Ultragenyx and Kyowa Kirin Announce Positive 64-Week Results for Crysvita® (burosumab) from Phase 3 Study in Children with X-linked Hypophosphatemia (XLH)

Stacey Gandler
Brand Nourishment

Paul Theisen
Patient Acquisition

Frank Burrell
Scientific Storytelling

Matthew Durham
Omnidynamic Marketing

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice

Matt Turner
Patient Affordability

Suma Ramadas, PhD
Medical Affairs

Liz Kane
Impactful Strategy

Daniel Sontupe
Market Access

Joey Cohen
Medication Adherence

Bud Bilanich
Success Coach

Pat Purcell
Meeting Engagement

Amy Giles
Increasing Engagement